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Abbreviation 
ALB albumin 
AUC area under the plasma concentration-time curve 
AUC(0-inf) area under the plasma concentration-time curve from 0 time extrapolated to infinity 
AUCR the ratios of the area under the curve of avatrombopag in the presence and absence of the inhibitor or inducer 
AUEC(0-28d) area under the effect curve for platelet count following avatrombopag dosing through 28 days after dosing 
BID twice a day 
BMI body mass index 
BM1 precursor production compartment 
BM2 transit compartment 
BM3 maturation compartment 
CIs confidence intervals 
CL/F apparent clearance 
Cmax maximum observed plasma concentration 
CLD chronic liver disease 
CYP cytochrome P450 
CV% coefficient of variation 
D1 duration for zero-order absorption 
DDI drug-drug interaction(s) 
Emax maximum increase in platelet counts 
F1 relative bioavailability 
GM geometric mean 
IIV interindividual variability 
IOV interoccasion variability 
IRB Institutional Review Board 
IS internal standard 
Ka absorption rate constant 
Kin zero-order production rate of platelet precursors 
Kout first-order maturation rate of platelet precursors 
LC-MS/MS liquid chromatography followed by tandem mass spectrometry 
LS least square 
ND not determined 
NONMEM nonlinear mixed-effects modeling software 
%CV or CV% percent coefficient of variation 
PBPK physiologically based pharmacokinetic 
PD Pharmacodynamics(s) 
PI(s) prediction interval(s) 
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PK Pharmacokinetic(s) 
PK/PD pharmacokinetic/pharmacodynamics 
QD once a day 
QF four times a day 
SD standard deviation 
SE standard error 
TPO thrombopoietin 
t½ terminal elimination phase plasma half-life 
TEmax time of maximum increase in platelet count 
tmax time at which the highest drug concentration occurs 
V/F apparent central volume 
1G tablet first-generation tablet 
2G tablet final to-be-marketed second-generation tablet 
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Preface 
Assessment of the pharmacokinetic (PK) and pharmacodynamic (PD) properties of new 
drug candidates is critical for their successful clinical development.  Multidisciplinary 
analyses are used to guide safe and effective dosing such as in vitro metabolism data, 
drug-drug interactions (DDI), ethnic differences, modeling and simulation, and clinical 
outcomes1.  The occurrence of DDI has the potential to significantly affect not only the 
safety and efficacy but also dosage regimen.  In the past several decades, we have 
typically evaluated the potential of DDI risk using in vitro and in vivo methods.  In this 
study, the author evaluated the PK/PD and DDI risk of avatrombopag maleate (E5501, 
DOPTELET®), thereafter avatrombopag, using physiologically based PK (PBPK) 
modeling and PK/PD simulation methods to optimize the dosage regimen in target 
patients. 
Thrombocytopenia is observed in patients with chronic liver disease (CLD), where it is 
associated with increased risk of bleeding with invasive procedures.  The current 
treatment options for thrombocytopenia are limited to platelet transfusions, which is the 
standard care, and a few surgical treatments such as splenectomy, splenic artery 
embolization, and transjugular intrahepatic portosystemic stent shunting.  In addition 
to the potential risks of transfusion reactions and infections, which can be fatal, repeated 
platelet transfusions are also associated with the development of platelet refractoriness, 
which is a serious concern for this patient population, who are at a higher risk of 
spontaneous bleeding, including gastrointestinal bleeding secondary to varices and 
coagulopathies, common comorbidities of CLD2. 
Avatrombopag, is an orally administered, small-molecule, thrombopoietin (TPO) 
receptor agonist that is believed to act on the TPO receptor c-Mpl, promotes 
megakaryocyte production, maturation, and the formation of platelets3,4.  
Avatrombopag is indicated for the treatment of thrombocytopenia in adult patients with 
chronic liver disease who are scheduled to undergo a procedure.  The recommended 
daily dose of avatrombopag is based on a patient’s baseline platelet count prior to a 
scheduled procedure.  Patients with a platelet count less than 40×109/L will receive 
avatrombopag 60 mg orally once daily for 5 consecutive days 10-13 days prior to a 
scheduled procedure whereas those with a platelet count of 40×109/L to less than 
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50×109/L will receive avatrombopag 40 mg orally once daily for 5 consecutive days 
10-13 days prior to a scheduled procedure5.  Drugs with TPO receptor agonist activity 
such as avatrombopag are expected to raise platelet count before invasive procedures, 
resulting in a reduction in platelet transfusion, and also enable more patients to undergo 
the procedure6.  
This thesis consists of 4 Chapters. The first chapter is to characterize and compare the 
PK, PD, and the safety and tolerability following a single dose of avatrombopag 
between healthy Japanese and White subjects.  The second chapter summarizes 
drug-drug interactions of avatrombopag as a victim with dual or selective cytochrome 
P450 (CYP) 2C9 and CYP3A inhibitors and inducers in healthy subjects.  The third 
chapter provides and overview of the population PK/PD relationship between plasma 
avatrombopag concentrations and platelet count developed using modeling methods.  
In Chapter 4, platelet count following avatrombopag administration with and without 
concomitant medication was simulated using the final population PK/PD model to 
explore potential dose adjustments.  The results of this simulation are referenced in the 
approved label in the United States5, and in the proposed labelling of the avatrombopag 
submission in the European Union. 
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Chapter 1  Pharmacokinetics, Pharmacodynamics, Safety, 
and Tolerability of Avatrombopag in Healthy Japanese and 
White Subjects 
 
 
Introduction 
Avatrombopag is an orally administered small-molecule thrombopoietin (TPO) receptor 
agonist that acts on the TPO receptor c-Mpl, activate the intracellular signaling system, 
and promote production of platelets and megakaryocytes from hemopoietic precursor 
cells, in the same way as TPO3,4.  
 
Avatrombopag is freely soluble in formic acid, slightly soluble in methanol, dehydrated 
ethanol, and acetic acid, and sparing soluble in water at pH 13.  However, it is 
practically insoluble in water below pH 12 and 0.1N hydrochloride.  In addition, 
studies with LLC-PK cells have shown that avatrombopag has low to moderate in vitro 
permeability.  In spite of the low permeability and solubility, avatrombopag is believed 
to have good oral bioavailability.  Preclinical studies have shown that, overall, 
avatrombopag was well absorbed ranged from approximately 50% to 90% in mouse, rat, 
dog and cynomolgus monkey.  The absolute bioavailability was unknown in human. 
 
Plasma protein binding of avatrombopag is greater than 96% in human plasma5 and it 
binds mainly to albumin.  The concentration in erythrocyte is approximately 50% of 
that in plasma.  
 
In a human mass balance study with a single oral administration of 20 mg 14C-labeled 
avatrombopag suspension, a major route of excretion of avatrombopag and its 
metabolites is by the fecal route, accounting for approximately 88% of the administered 
dose in healthy male subjects.  The excretion in urine is approximately 6% of the dose.  
The majority of total radioactivity was excreted by 72 hours in urine and by 168 hours 
in feces.  Approximately 34% and 44% of the dose is unchanged drug and 4-hydroxy 
derivative (the primary metabolite of avatrombopag) in feces, respectively.  No 
metabolites were detectable in plasma. 
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Ｉn vitro study data using human hepatocytes and recombinant human cytochrome P450 
(CYP) suggests that avatrombopag is metabolized by CYP3A4 and CYP2C9.    The 
metabolic and elimination pathways of avatrombopag in humans were shown in 
Figure1-17. 
 
 
 
Figure 1-1  Metabolic and Elimination Pathway of Avatrombopag in Humans 
Fa is assumed to be more than 0.65 from the human mass balance study.  The dotted line represents an 
uncertain pathway. CYP, cytochrome P450; Fa, fraction of administered dose that is absorbed. 
 
The nonclinical pharmacology and toxicology data supported proceeding to clinical 
testing, therefore, a single-dose study was conducted to characterize and compare the 
PK (including the food effect), PD (platelet count), and the safety and tolerability 
between healthy Japanese and White subjects. 
 
Method 
Study Design 
A randomized, open-label, 5-treatment period, single-dose study was conducted to 
assess the PK and PD of avatrombopag and to explore the effects of ethnicity.  The 
dose-proportionality of PK, the effect of food on exposure, and the safety and 
tolerability were compared between Japanese and White subjects.  Subjects were 
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randomly assigned 1:1:1:1 stratified by race to 1 of 4 treatment periods (sequences A to 
D) as shown in Table 1-1.  Each subject received a single oral dose of 40 or 60 mg 
under fasted and fed (high-fat meal) conditions or 20 mg under fed conditions.  The 
washout period of 28 days or longer was set between the administration of 
avatrombopag in each period. 
 
Table 1-1  Study Design and Dosing Paradigm 
Treatment Period 
Food condition 
1 
Fed 
2 
Fed 
3 
Fasted 
4 
Fasted 
5 
Fed 
Sequence A 40 mg 60 mg 40 mg 60 mg 20 mg 
Sequence B 60 mg 40 mg 40 mg 60 mg 20 mg 
Sequence C 40 mg 60 mg 60 mg 40 mg 20 mg 
Sequence D 60 mg 40 mg 60 mg 40 mg 20 mg 
The washout period of 28 days or longer was set between the administration of avatrombopag in each 
period. 
 
This study was conducted in a total of 24 healthy Japanese and 24 healthy White male 
and female subjects at a single center (California Clinical Trials Medical Group) in the 
United States, according to the principles of the Declaration of Helsinki and Good 
Clinical Practice guidelines.  The study protocol was approved by the Institutional 
Review Board (IRB), and informed consent for all participants was obtained prior to 
screening.   
 
Subjects 
Healthy male and female 24 Japanese or 24 white subjects aged 20 to 55 years with 
body mass index (BMI) from 18 to 28 kg/m2 were included.  Japanese subjects were 
defined as having been born in Japan or Japanese parents and grandparents, living 
outside of Japan for <5 years, and keeping their Japanese lifestyle, habits, and diet.  
Subjects were excluded from this study if their platelet counts were less than the limit of 
normal or more than 350×109/L at the time of screening and at each baseline 
assessment. 
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Study Drug Formulation and Administration 
The study drug was provided as a tablet containing 20 mg of avatrombopag 
(1-(3-chloro-5-{[4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazin-l-yl)-1,3-thiazol-2-yl]
carbamoyl}-2-pyridyl) piperidine-4-caboxylic acid monomaleate) by Eisai Co., Ltd.  
Under fasted conditions, subjects were administered study drug following an overnight 
fast of at least 10 hours with 240 m of water.  Subjects were not allowed any food for 
at least 4 hours after dosing.  Under fed conditions, subjects started taking a high-fat 
meal (approximately 800 to 1000 kcal, with at least 50% calories derived from fat) 
30 minutes before the time to receive the study drug8,9.  Subjects were administered 
study drug with 240 mL of water at 30 minutes after the start of the meal.  Subjects 
were not allowed any additional food for a period of 4 hours after dosing.  
 
Bioanalytical Methods 
Plasma was separated by centrifugation at 1500×g for 10 min at 4°C.  The plasma 
samples were stored in polypropylene tubes at approximately –20°C until analysis.  
The plasma concentrations of avatrombopag were quantified by using a validated liquid 
chromatography followed by tandem mass spectrometry (LC–MS/MS) in human 
plasma with sodium heparin as anticoagulant.  The method utilized a protein 
precipitation procedure to extract avatrombopag and deuterated-internal standard (IS, 
YM-385029; avatrombopag-d10) from 100 μL of human plasma, a reversed-phase 
high-performance liquid chromatography C8 column, 5 μm, 50×2.0 mm column, with a 
mobile phase gradient using 10 mmol/L ammonium formate in water, pH4 and 
methanol:acetonitrile (1:1) to separate the analyte from the matrix and an LC–MS/MS 
instrument with positive 
electrospray ionization multiple reaction monitoring mode to quantify the analyte.  The 
mass spectrometer was operated in positive electrospray ionization mode and the 
resolution setting used was unit for both Q1 and Q3.  The multiple reaction monitoring 
transition was m/z 649.2→267.1 for avatrombopag and m/z 659.4→267.1 for the IS.  
The interrun accuracy was <4.50%; interrun precision was <10.2% and intrarun 
accuracy was <6.50%; intrarun precision was <12.3% with all met the acceptance 
criteria within ±15%.  At the lower limit of quantitation of 1.00 μg/L, the interrun 
accuracy was <-7.20%; interrun precision was <15.1%; intrarun accuracy was <–13.1%; 
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intrarun precision was <14.8% with all met the acceptance criteria within ±20%.  The 
calibration curve ranged from 1.00 μg/L to 500 μg/L for avatrombopag.  Platelet count 
was determined at study site through a local clinical laboratory. 
 
PK Assessment 
Serial blood samples for measuring plasma avatrombopag concentration were collected 
predose and 1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, 72, and 96 hours after dosing.  
Noncompartmental PK analysis was performed to derive PK parameters of 
avatrombopag in plasma using Phoenix WinNonlin software (Pharsight, Mountain View, 
California).  PK parameters included the maximum observed plasma concentration 
(Cmax), time at which the highest drug concentration occurs (tmax), the area under the 
plasma concentration-time curve from 0 time to time extrapolated to infinity (AUC(0-inf)), 
and the terminal elimination phase plasma half-life (t½). 
 
PD Assessment 
Blood samples for determination of platelet count (normal range: apparently 150 to 
400×109/L) were collected predose and on days 5, 6, 11, 14, 21, 24, and 28 after 
avatrombopag administration.  The change from baseline in platelet count for each 
time point after avatrombopag dosing was estimated.  Noncompartmental analysis for 
drug effect was performed to derive PD parameters of avatrombopag in plasma using 
PhoenixWinNonlin software.  PD parameters included the observed time of maximum 
increase in platelet count following avatrombopag dosing in each treatment (TEmax), the 
maximum increase in platelet counts following avatrombopag dosing observed in each 
treatment (Emax), and the area under the effect curve for platelet count following 
avatrombopag dosing (day 1 in each treatment) through 28 days after dosing (Day 28 in 
each treatment) (AUEC(0–28d)). 
 
Statistical Analysis 
All statistical programming and analyses were performed using Phoenix WinNonlin and 
SAS software, version 9.2 or later (SAS Institute, Inc, Cary, North Carolina). 
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1) Comparison of ethnicity 
Comparison between Japanese subjects (test) and white subjects (reference) at doses of 
40 and 60 mg was made by estimating the percentage of geometric least-squares mean 
(Japanese/white) and 90% confidence intervals (CIs).  Considering PK variability, it 
was determined that we may conclude that PK was similar between Japanese and white 
subjects if the percentage of geometric least squares mean was within 0.77 and 1.3. 
2) Food effect 
Food effect was assessed using ratios of PK parameters (fed/fasted) of the geometric 
least-squares mean and 90%CIs for PK parameters using a mixed-effect model. 
3) Dose proportionality 
Dose proportionality was evaluated using a power model to assess the slope parameter 
and 95%CIs using the equation log(Y) = α+ βlog(X), where X is dose and Y is Cmax or 
AUC.  Dose proportionality was concluded if the slope was contained within the 
interval of 0.7 to 1.310. 
 
Results 
1) Demographic and Disposition 
Forty-eight healthy subjects were enrolled and randomized, 36 of whom (18 subjects in 
each race group) completed all planned study procedures.  The baseline demographics 
of the study participants are summarized in Table 1-2.  The mean weight and height of 
the Japanese subjects were slightly lower than those of the white subjects, but there 
were no other notable differences between Japanese and white subjects in demographic 
characteristics.  Among the 12 subjects who discontinued the study, 3 subjects were 
discontinued due to noncompliance, 7 subjects withdrew consent, 1 subject was 
discontinued due to an adverse event of influenza-like illness, and 1 subject was 
discontinued due to a decrease in pulse rate (60 mg fed conditions). 
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Table 1-2  The Baseline Demographic Characteristic of Subjects 
Race N Sex, n 
Male/female 
Age, y Weight, kg Height, cm BMI, kg/m2 
Japanese 24 12/12 35 (22-54) 62 (42-87) 165 (148-180) 23 (19-28) 
White 24 12/12 35 (23-51) 70 (50-91) 170 (152-187) 24 (20-28) 
The values were shown as Mean (Min-Max).  BMI = body mass index. 
 
2) PK Results 
Mean (+ standard error) plasma avatrombopag concentration-time profiles under fed 
conditions by race group are presented in Figure 1-2.  Corresponding PK parameters 
are summarized in Table 1-3.  
 
 
Figure 1-2  Mean (+SE) plasma avatrombopag concentration-time profiles 
following single oral doses of 20, 40, and 60 mg under fed conditions in Japanese 
(dot black line) and White (solid blue line) subjects. 
Semi-log scale. SE, standard error. 
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Table 1-3 Pharmacokinetic parameters of avatrombopag and ethnic comparison 
following single oral dose administration in Japanese and White subjects 
Race Food condition 
Dose 
(mg) N 
Mean (SD) 
Cmax 
(ng/mL) 
tmaxa 
(h) 
t½ 
(h) 
AUC(0-inf) 
(ng•h/mL) 
Japanese 
Fed 20 18 109 (26.9) 7 (3-12) 16.4 (2.09) 3220 (831) 
Fed 40 23 208 (54.1) 6 (3-12) 16.1 (1.96) 5870 (1790) 
Fed 60 23 332 (93.3) 7 (3-24) 16.0 (1.54) 9400 (2240) 
White 
Fed 20 18 95.4 (49.1) 7 (3-24) 18.6 (3.90) 3160 (2350) 
Fed 40 24 164 (62.8) 8 (3-24) 18.0 (4.13) 5900 (3560) 
Fed 60 24 284 (122) 7.5 (3-24) 18.2 (3.95)b 10000 (7130)b 
Japanese/White 
%GM ratio 
[90% CIs] 40  
129 
[110, 151]   
108 
[89.1, 131] 
%GM ratio 
[90% CIs] 60  
121 
[103, 142]   
104 
[85.7, 127] 
a: Median (range); b: n=23; AUC(0-inf) = area under the concentration-time curve from zero to infinity; CI 
= confidence intervals; Cmax = maximum plasma concentration; %GM ratio = geometric mean of 
Japanese/ White × 100; tmax = time to maximum plasma concentration; t½ = terminal half-life. 
 
Following single-dose administration of 20, 40, and 60 mg, avatrombopag under fed 
conditions attained Cmax at approximately 6 to 8 hours after dosing in both Japanese and 
White subjects.  Mean t½ values were similar in Japanese and Whites, ranging from 16 
to 17 hours in Japanese and from 18 to 19 hours in White subjects.  Avatrombopag 
Cmax at 40- and 60-mg doses in Japanese subjects were slightly higher than those in 
White subjects.  The relative differences expressed as percentages of geometric 
least-squares means (Japanese/White) for Cmax indicate that Japanese Cmax values were 
29% higher than those of Whites.  In contrast, AUC(0-inf) values were similar in both 
race groups for the 40- and 60-mg doses.  Mean avatrombopag Cmax and AUC values 
each increased in a dose-proportional manner following single dose administration of 20, 
40, and 60 mg for both race groups under fed conditions. 
Overall, consumption of a high-fat meal did not have clinically important effects on the 
rate or extent of avatrombopag absorption. However, a clinically important outcome of 
this study was the observation that consumption of a high-fat meal was associated with 
substantially reduced intersubject variability of avatrombopag PK (Table 1-4) compared 
to dosing under fasted conditions; 23.7% to 30.0% for under fed conditions vs. 46.1% to 
53.0% under fasted conditions in Japanese, 38.2% to 62.3% for under fed conditions vs. 
51.9% to 60.8% under fasted conditions in White.  This finding led to the 
recommendation in further clinical testing to administer avatrombopag with food.  
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Table 1-4  The Food Effect on Avatrombopag PK parameters 
Race PK Parameters 
Dose 
(mg) 
N Geometric LS Mean (%CV) 
%Ratio 90% Confidence Interval of %Ratio Fed Fasted Fed Fasted 
Japanese 
Cmax 
(ng/mL) 
40 23 18 199 (26.0) 238 (46.1) 83.9 68.6, 103 
60 23 18 320 (28.1) 333 (53.0) 96.2 78.6, 118 
tmax 
(h) 
40 23 18 6 (3-12) 5 (3-12)   
60 23 18 7 (3-24) 5 (4-7)   
AUC(0-inf) 
(ng•h/mL) 
40 23 18 5640 (30.0) 6130 (47.9) 91.9 75.6, 112 
60 23 18 9130 (23.7) 8430(51.7) 108 89.2, 132 
White 
Cmax 
(ng/mL) 
40 24 21 155 (38.2) 117 (59.5) 132 108, 164 
60 24 20 263 (42.8) 183 (60.1) 144 116, 179 
tmax 
(h) 
40 24 21 8 (3-24) 6 (4-24)   
60 24 20 7.5 (3-24) 5 (4-24)   
AUC(0-inf) 
(ng•h/mL) 
40 24 21 5210 (53.3) 3340 (51.9) 156 126, 194 
60 23 20 8690 (62.3) 4840 (60.8) 180 144, 224 
%Ratio = Fed/ Fasted × 100. a: Median (range); AUC(0-inf) = area under the concentration-time curve from 
time 0 to infinity; Cmax = maximum drug concentration; tmax = time to reach maximum concentration after 
drug administration. 
 
Geometric least-squares mean values at 40- and 60-mg doses comparing the fed and 
fasted administrations were 83.9% and 96.2% for Cmax, 91.9% and 108% for AUC(0-inf) 
in Japanese subjects.  Geometric least-squares mean values at 40- and 60-mg doses 
comparing the fed and fasted administrations were 132% and 144% for Cmax, 156% and 
180% for AUC(0-inf) in White subjects.  The 90% CIs of neither percentage ratio met 
the bioequivalence criteria due to large variability of PK parameters, especially under 
fasted conditions.  Coadministration with a high-fat meal did not affect tmax of 
avatrombopag in either race group administered single 40- or 60-mg doses. 
 
3) PD Results 
Increases in platelet count following single doses of avatrombopag were observed at 20- 
to 60-mg doses.  Platelet counts generally increased to a maximum mean change from 
baseline of approximately 50 to 110×109/L on days 8 to 11, then decreased to 
approximate baseline levels by the end of the treatment period (day 28) as illustrated in 
Figure 1-3.  Although characterized by relatively high variability, the response of 
platelet count was similar between race groups.  
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Figure 1-3 Mean platelet count vs time profile following single dose under fed 
conditions. 
The PD parameters were comparable between Japanese and White subjects under fed 
conditions (Table 1-5).  Across all treatments and race groups, the median observed 
time of maximum increase in platelet count was 8 to 11 hours.  Only 1 White subject 
in each cohort administered 40 and 60 mg fed had a maximum increase in platelet 
counts >500×109/L.  The systemic exposure to avatrombopag appeared to be 
correlated with area under the effect curve for platelet count over 28 days of treatment. 
 
Table 1-5  Pharmacodynamic parameters of avatrombopag following single oral 
dose administration in Japanese and White subjects under fed condition. 
Race 
Food 
condition 
Dose 
(mg) N 
Mean (SD) 
Emax 
(109/L) 
TEmaxa 
(day) 
AUC(0-28d) 
(day•109/L) 
Japanese 
Fed 20 18 300 (55.3) 8 (5-11) 432 (1020) 
Fed 40 23 323 (66.6) 8 (5-11) 887 (988) 
Fed 60 23 333 (61.9) 8 (8-28) 1160 (671) 
White 
Fed 20 18 302 (79.8) 11 (8-21) 743 (779) 
Fed 40 24 329 (69.4) 8 (8-28) 1260 (602) 
Fed 60 23 340 (80.9) 11 (8-21) 1430 (772) 
a: Median (range); AUEC(0-28d) = area under the effect curve for platelet count following avatrombopag 
dosing (Day 1 in each treatment) through 28 days after dosing (Day 28 in each treatment); Emax = 
maximum increase in platelet counts following avatrombopag dosing observed in each treatment; SD = 
standard deviation; TEmax = observed time of maximum increase in platelet count following 
avatrombopag dosing in each treatment. 
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Discussion 
The high PK variability seen in the fasted state may mask potential PK difference 
between Japanese and White subjects and assessment of dose-proportionality, therefore 
these evaluations were conducted using the PK and PD data under fed condition. 
 
Following the oral single-dose administration under fed condition, avatrombopag 
showed linear PK across a range of 20 to 60 mg dose.  The absorption of 
avatrombopag is relatively slow, with peak plasma avatrombopag concentrations 
observed at approximately 5 to 8 hours postdose.  Avatrombopag is characterized by 
poor aqueous solubility, and the slow absorption rate may reflect solubility-rate–limited 
absorption.  Importantly, poor solubility did not impact the rate or extent of drug 
absorption across the range of doses tested, as evidenced by confirmation of dose 
proportionality in Cmax and AUC for doses ranging from 20 to 60 mg.  Values of tmax 
and t½ are constant and independent of dose.   
 
Administration of avatrombopag with a high-fat meal did not have an impact on the rate 
or extent of absorption in Japanese subjects.  However, exposure was increased in 
white subjects when avatrombopag was administered with a high-fat meal.  The 
apparent effects of a high-fat meal on the exposure in White subjects is most likely a 
reflection of high variability and lower than expected PK exposures under fasted 
conditions rather than a true food effect in the White subjects only.  An observation of 
avatrombopag PK was that the avatrombopag plasma exposures after single dosing 
under fasted condition were characterized by high intersubject variability, with 
coefficient of variation (CV%) of approximately 46.1% to 60.8%.  Importantly, the 
intersubject variability was substantially reduced under fed conditions, which ranged 
from approximately 23.7% to 30% CV% in Japanese or approximately 38.2% to 62.3% 
CV% in Whites.  In previous study, a low-fat (500 kcal, containing fat content of 
approximately 5% of total caloric content of the meal) or high-fat meal did not affect 
avatrombopag AUC and Cmax, but reduced the intra-subject variability by 50 to 70% and 
inter-subject variability by 40 to 49%11.  Interestingly, food affected only the 
variability in the derived PK parameters without influencing the rate or extent of 
absorption, as shown by the lack of an effect of food on mean values of Cmax, AUC, and 
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tmax.  These results could be explained by food potentially prolonging gastrointestinal 
transit and thus allowing greater uniformity of solubility of avatrombopag, thereby 
reducing variability in absorption.  Based on this result, avatrombopag is administered 
under fed conditions for clinical use.   
 
While substantially delayed relative to PK, avatrombopag increased platelet count in a 
dose-dependent manner.  After single doses, platelet count reached a maximum by 11 
days postdose and then returned to baseline level by 27 days postdose.  This delayed 
response of platelet count is predicted from the hypothesized mechanism of action for 
avatrombopag, which acts on the TPO receptor concurrently with endogenous TPO and 
differentiation into megakaryocytes, and thereby increases the number of circulating 
platelets.  Given this delay in PD response and the known natural fluctuation of 
platelet count during the day, small variations in PK generally have no significant 
influence on platelet response.  
 
The PK and PD of avatrombopag were similar between Japanese and White subjects, 
thus enabling the possibility of the same dosage regimen and simultaneous global 
clinical development, which may lead to faster access for the patients who need these 
new products.  
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Chapter 2  Pharmacokinetic/Pharmacodynamic Drug-drug 
Interactions of Avatrombopag when Co-administered with 
Dual or Selective CYP2C9 and CYP3A Interacting Drugs 
 
 
Introduction 
Avatrombopag metabolism is mediated by CYP2C9 and CYP3A to form 4-hydroxy 
metabolite.  The relative percentage contribution of the two major CYP enzymes 
toward the CYP dependent metabolism of avatrombopag was assessed using the relative 
activity factor in human liver microsomes and recombinant CYP enzyme12.  Among 
the two drug-metabolizing CYP isoforms evaluated, the contributions of CYP2C9 in 
4-hydroxy cis and trans metabolites were 76.2% and 17.1%, respectively.  The 
contribution of CYP3A4 on avatrombopag 4-hydroxy cis and trans metabolites were 
23.8% and 82.9% (Table 2-1).  Overall, the data suggested that avatrombopag 
metabolism is mediated by CYP2C9 and CYP3A equally to form 4-hydroxy metabolite.  
These CYP enzymes seemed likely to contribute ≥25% of total clearance each based on 
in vitro data. 
 
Table 2-1  Percent Contributions of CYP2C9 and CYP3A4 to the Formation of 
4-Hydroxyl Metabolite of Avatrombopag 
Metabolite CYP Isoform Tested Relative Contribution (%) 
4-hydroxy cis 
CYP2C9 76.2 
CYP3A4 23.8 
4-hydroxy trans 
CYP2C9 17.1 
CYP3A4 82.9 
Relative Contribution = % Contribution of each CYP / Total % Contribution from each metabolite. 
% Contribution = [(Vmax/Km in rCYP)/(Vmax/Km in HLM)] ∙ RAF ∙ 100. 
RAF = (Vmax/Km of CYP in HLM)/(Vmax/Km of rCYP). 
 
Physiologically based pharmacokinetic (PBPK) modeling and simulation can be used to 
predict the PK behavior of drug using compound-specific parameters from nonclinical 
and clinical data13.  PBPK models were developed for avatrombopag using SimCYP 
(version 14.1) software (www.simcyp.com) and drug-drug interaction (DDI) 
simulations of avatrombopag were performed with the CYP inhibitors itraconazole, 
ketoconazole, fluconazole, verapamil, sulphaphenazole, and with the CYP inducer 
rifampin.  The predicted DDI risks were calculated from the ratios of the area under 
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the curve of avatrombopag in the presence and absence of the inhibitor or inducer 
(AUCR) in Table 2-2.  
 
Table 2-2  Predicted AUC Ratios (AUCR) and DDI risk for Avatrombopag 20 mg 
oral tablet. 
Concomitant drug AUCRa Predicted DDI riskb 
Itraconazole 200 mg QF (strong CYP3A inhibitor) 1.29-1.78 Small 
Fluconazole 400 mg QD (moderate CYP2C9 and CYP3A 
inhibitor) 2.11-3.59 Moderate 
Ketoconazole 200 mg BID (strong CYP3A inhibitor) 1.44-2.27 Small-Moderate 
Sulphaphenazole 2 g QD (CYP2C9 inhibitor) 1.48-2.30 Small-Moderate 
Verapamil 240 mg QD (moderate CYP3A) 1.17-1.47 Negligible-Small 
Rifampin 600 mg QD (strong CYP3A and moderate CYP2C9 
inducer) 0.22-0.43 Moderate 
a: the range of AUCR which was derived from 2 different absorption models and 3 different clearance 
models. 
b: Impact qualified according to “FDA Guidance” for Industry. Drug Interaction Studies – Study Design, 
Data Analysis, Implications for Dosing, and Labeling Recommendations. February 2012. 
AUCR, the ratios of the area under the curve of avatrombopag in the presence and absence of the inhibitor 
or inducer; BID, twice a day; QD, once a day; QF, four times a day  
 
CYP2C9 and CYP3A-mediated interactions were considered as the highest-risk 
metabolism-based interactions that might affect the exposure of avatrombopag 
according to in vitro metabolism data and PBPK simulations.  To evaluate the 
maximum potential effect of metabolism-based inhibition, fluconazole was selected as a 
moderate dual inhibitor of CYP2C9 and CYP3A.  Fluconazole is the only reference 
CYP2C9 inhibitor recommended in the European Medicines Agency guideline14, and 
among those noted in the Food and Drug Administration15-17, and Ministry of Health, 
Labour and Welfare draft guidance18.  Itraconazole was selected as a strong CYP3A 
inhibitor to evaluate the impact of strong CYP3A inhibition, and has been shown not to 
impact the CYP2C9 activity19,20.  Although the inhibition potential of itraconazole is 
considered to be less than that of ketoconazole21, itraconazole has been used in clinical 
drug–drug interaction studies as a typical inhibitor of CYP3A since ketoconazole was 
reported to cause serious safety concerns related to liver toxicities22.  To evaluate the 
maximum effect of metabolism-based induction, rifampin was selected as a strong 
CYP3A inducer with moderate CYP2C9 inducing potency14,17,18. 
A clinical drug interaction study was therefore conducted with the above-mentioned 
three drugs to evaluate the impact of those drugs on PK and PD and safety of 
avatrombopag and provide appropriate guidance to the prescribing physicians on 
- 20 - 
 
concomitant administrations of avatrombopag with drugs that are known CYP2C9- 
and/or CYP3A-interacting drugs. 
 
Method 
Study Design 
This study was an open-label, drug-drug interaction study at a single center (Worldwide 
Clinical Trials Early Phase Services, LLC) in the United State.  The study was divided 
into three Parts.  In Part A, the effects of steady-state dosing of a moderate inhibitor of 
CYP2C9 and CYP3A (i.e. fluconazole) on single dose PK of avatrombopag were 
assessed.  In Part B, the effects of steady-state dosing of a strong CYP3A inhibitor 
(itraconazole) on the single dose PK of avatrombopag were assessed.  In Part C, the 
effects of steady-state dosing of a strong CYP3A and moderate CYP2C9 inducer 
(rifampin) on the single dose PK of avatrombopag were assessed.  There were 16 
subjects enrolled in each study part, and each part was conducted in parallel.  Each part 
of the study consisted of two treatment periods: Period 1 (administration of a single oral 
dose of avatrombopag 20-mg alone) and Period 2 (administration of oral doses of each 
inhibitor or inducer alone and concomitant administration of a single oral dose of 
avatrombopag 20-mg with each inhibitor or inducer [fluconazole in Part A, itraconazole 
in Part B, or rifampin in Part C]).  Each period was separated by a washout interval of 
at least 28 days.  Subjects whose platelet count exceeded 600 × 109/L during the study 
were to be discontinued.  Subjects whose platelet count exceeded 400 × 109/L were to 
be administered low-dose aspirin at the discretion of the investigator.  This study was 
approved by the IRB of the site, and conducted in accordance with the principles of the 
Declaration of Helsinki and Good Clinical Practice guidelines.  All participants were 
given the explanation of the study, and written informed consent was obtained prior to 
screening. 
 
Subjects 
A total of 48 healthy, nonsmoking subjects, male and female aged 18–55 years with 
BMI 18–28 kg/m2 were enrolled.  There were 16 healthy male and female subjects in 
each Part.  Subjects were excluded if: their platelet count was not between the lower 
limit of normal and 300 × 109/L at the time of screening and at baseline of each period; 
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they used any prescription drugs or St. John’s Wort within 4 weeks before first dosing 
of avatrombopag; they took over-the-counter medications within 2 weeks before; or 
they took any food or beverages (e.g. alcohol, grapefruit juice) that might have affected 
the various drug metabolizing enzymes and transporters within 1 week before first 
dosing of avatrombopag.  Subjects whose platelet count exceeded 600×109/L during 
the study were to be discontinued.   
 
Study Drug Formulation and Administration 
Avatrombopag 20-mg tablet was administrated under fed conditions (approximately 
800–1000 calories, containing fat content of approximately 50% of total caloric content 
of the meal).   
Part A: Subjects were administered a single oral dose of avatrombopag 20 mg on Day 1 
of Period 1.  Subjects were administered fluconazole (Diflucan 200-mg tablet; Pfizer, 
NY, USA) 400 mg once daily on Days 1 to 16 and a single dose of avatrombopag 20 mg 
on Day 7 in Period 2.  Each dose of avatrombopag was administered 30 min after the 
start of the meal. 
Part B: Subjects were administered a single oral dose of avatrombopag 20 mg on Day 1 
of Period 1.  Subjects were administered itraconazole (Sporanox 100-mg capsule; 
Janssen Pharma, NJ, USA) 200 mg twice daily on Day 1 and 200 mg once daily on 
Days 2 to 16 of Period 2.  A single dose of avatrombopag 20 mg was administered on 
Day 7 of Period 2.  Each dose of avatrombopag was administered 30 min after the start 
of the meal.  
Part C: Subjects were administered a single oral dose of avatrombopag 20 mg on Day 1 
of Period 1.  In Treatment Period 2, rifampin (Rifadin 200-mg capsule; Sanofi-aventis 
U.S. LLC, Bridgewater NJ, USA) 600 mg was administered once daily on Days 1 to 16.  
To avoid a food effect on rifampin absorption23, each dose was administered 1 h before 
subjects consumed a meal.  On Day 7 of Period 2, rifampin 600 mg and avatrombopag 
20 mg were administered 1 h before starting meal consumption and 30 min after starting 
meal consumption, respectively. 
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Bioanalytical Methods 
The Bioanalytical Methods refer to the Method in Chapter 1.  In addition, lack of 
bioanalytical interference between avatrombopag and the inhibitor or inducer 
(fluconazole, itraconazole and rifampin) were documented prior to plasma sample 
analysis. 
 
PK Assessments 
Serial blood samples for measuring plasma avatrombopag concentration were collected 
predose and 1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, 72, 96, 144, and 216 hours after 
avatrombopag administration.  Noncompartmental PK analysis method refers to 
Chapter 1. 
 
PD Assessments 
Blood samples for determination of platelet count (normal range: apparently 150 to 
400×109/L) were collected predose and on days 3, 4, 5, 6, 7, 8, 12, 14, 21, and 28 after 
avatrombopag administration.  PD analysis method refers to Chapter 1. 
 
Statistical Analysis 
Statistical analyses were performed using Phoenix WinNonlin and SAS (Version 9.3, 
SAS institute Inc., Cary, NC, USA) software. PK data were summarized using 
descriptive statistics.  Log transformed Cmax and AUC(0-inf) and untransformed t½ were 
analyzed using mixed effect models to yield the ratios (test/reference) of geometric least 
square means and 90% CIs, and the difference between test and reference and 90% CIs, 
respectively.  The mixed model included period as a fixed effects and subjects as a 
random effect.  A nonparametric (Hodges–Lehmann) method was used to estimate the 
median difference between test and reference for tmax. 
The statistical analysis for PD parameters was performed on untransformed data due to 
the presence of negative values using a mixed effect model with period as a fixed effect 
and subject as a random effect.  Treatment means, difference of treatment means and 
90% CIs were presented on the untransformed data. 
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Results 
1) Part A; Fluconazole, a dual moderate inhibitor of CYP2C9 and 
CYP3A 
Avatrombopag plasma concentrations were elevated when avatrombopag was 
coadministered with fluconazole compared to avatrombopag alone (Figure 2-1).  
Coadministration of avatrombopag and fluconazole increased Cmax and AUC of 
avatrombopag by 1.17-fold and 2.16-fold, respectively.  Coadministration of 
fluconazole extended t½ of avatrombopag by approximately 2.0-fold (19.7 h in 
avatrombopag alone vs. 39.8 h in avatrombopag+fluconazole) but tmax was unaffected 
by fluconazole coadministration (Table 2-3).  Consistent with the PK effect of 
fluconazole, the mean profile of platelet count over time was greater during 
coadministration with fluconazole compared with avatrombopag alone.  
Coadministration of avatrombopag and fluconazole increased Emax by 1.66-fold 
(calculated as a ratio of mean value for coadministration of fluconazole and 
avatrombopag to mean for avatrombopag alone) and the mean difference in Emax 
between two treatments was 21.19×109/L.  There was approximately a 1.47-fold 
increase in AUEC(0-28d) with coadministration of avatrombopag and fluconazole (Table 
2-4).  Relative to the magnitude of PK interaction, coadministration with fluconazole 
resulted in a PD interaction to a lesser degree; however, the >20×109/L mean difference 
in Emax with fluconazole coadministration is considered a clinically significant effect. 
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Figure 2-1 Mean (+ SD) plasma concentration–time profiles of avatrombopag 
following administration of avatrombopag alone and concomitantly with 
fluconazole.  
n = 16  
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Table 2-3.  Summary of pharmacokinetic parameters of avatrombopag and statistical comparisons following administration of 
avatrombopag 20 mg with or without fluconazole, itraconazole and rifampin. 
Treatment 
(Test:Reference) Parameter 
n Arithmetic mean (Standard deviation) LS Mean 
Ratio 
90% 
confidence 
interval Test Reference Test Reference 
Avatrombopag+Fluconazole: 
avatrombopag 
Cmax (μg/L) 16 16 115 (34.5) 101 (37.1) 1.17 0.964, 1.42 
AUC(0-inf) (μg∙h/L) 15 16 6800 (2340) 3170 (1160) 2.16 1.71, 2.72 
t½ (h) 15 16 39.8 (5.12) 19.7 (2.44) 20.2a 18.4, 22.1a 
tmax (h) 16 16 7 (5, 24) 7 (4, 12) ND ND 
Avatrombopag+Itraconazole: 
avatrombopag 
Cmax (μg/L) 13 16 123 (55.0) 106 (31.2) 1.07 0.855, 1.35 
AUC(0-inf) (μg∙h/L) 13 16 4990 (3070) 3380 (1530) 1.37 1.10, 1.72 
t½ (h) 13 16 28.0 (9.77) 19.6 (3.25) 8.47a 5.25, 11.7a 
tmax (h) 13 16 6 (3, 12) 6 (4, 12) ND ND 
Avatrombopag+Rifampin: 
avatrombopag 
Cmax (μg/L) 14 16 108 (33.5) 103 (37.9) 1.04 0.882, 1.23 
AUC(0-inf) (μg∙h/L) 13 16 1790 (776) 3340 (1760) 0.568 0.465, 0.623 
t½ (h) 13 16 9.77 (1.49) 20.3 (5.34) -10.5a -12.7, -8.21a 
tmax (h) 14 16 5 (2, 12) 6 (3, 8) ND ND 
Cmax, AUC(0-inf) and t½ presented as Arithmetic means (Standard deviation), tmax presented as Median (range).  a: LS mean difference (90% confidence interval) 
AUC(0-inf), area under the concentration-time curve from 0 time extrapolated to infinite time; Cmax, maximum observed concentration; LS, least square; ND, not determined; t½, terminal elimination phase 
half-life; tmax, time at which the highest drug concentration occurs. 
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Table 2-4.  Summary of pharmacodynamic parameters and statistical comparisons following administration of avatrombopag 
20 mg with or without fluconazole, itraconazole and rifampin. 
Treatment 
(Test:Reference) Parameter 
n Arithmetic mean (Standard deviation) LS Mean 
Difference  
90% confidence 
interval Test Reference Test Reference 
Avatrombopag+Fluconazole: 
avatrombopag 
Emax (109/L) 16 16 307 (64.5) 285 (59.9) 21.19 2.89, 39.49 
TEmax (day) 16 16 10 (7, 12) 10 (7, 12) ND ND 
AUEC(0-28d) (h∙109/L) 16 16 23300 (14100) 15800 (7790) 7480 2400, 12560 
Avatrombopag+Itraconazole: 
avatrombopag 
Emax (109/L) 13 16 307 (84.1) 314 (73.2) -5.92 -30.98, 19.14 
TEmax (day) 13 16 10 (3, 21) 10 (4, 28) ND ND 
AUEC(0-28d) (h∙109/L) 12 14 25100 (18100) 18100 (11800) 6658 1200, 12116 
Avatrombopag+Rifampin: 
avatrombopag 
Emax (109/L) 14 16 307 (40.4) 317 (42.1) -9.73 -19.50, 0.05 
TEmax (day) 14 16 7 (5, 12) 8.5 (5, 28) ND ND 
AUEC(0-28d) (h∙109/L) 14 15 3460 (10300) 15300 (8600) -12001 -14905, -9096 
Emax and AUEC(0-28d) presented as Arithmetic means (Standard deviation), TEmax presented as Median (range).  
AUEC(0-28d), area under the effect curve for platelet count; Emax, maximum platelet counts; LS, least square; ND, not determined; TEmax, observed time of maximum 
increase in platelet counts 
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2) Part B; Itraconazole, a strong CYP3A inhibitor 
Mean plasma concentrations of avatrombopag during coadministration of itraconazole 
were slightly higher than after avatrombopag alone (Figure 2-2).  Following 
coadministration of itraconazole, Cmax and tmax of avatrombopag did not show apparent 
difference whereas AUC(0–inf) increased by 1.37-fold and t½ was prolonged 1.4-fold 
compared to avatrombopag alone (Table 2-3). 
The mean profile of platelet count over time was similar between coadministration with 
itraconazole and avatrombopag alone.  The mean difference in Emax for avatrombopag 
alone and for coadministration with itraconazole was not statistically significant (Table 
2-4), indicating that itraconazole has no impact on the PD effect of avatrombopag. 
 
Figure 2-2 Mean (+ SD) plasma concentration–time profiles of avatrombopag 
following administration of avatrombopag alone and concomitantly with 
itraconazole. 
avatrombopag alone: n=16, avatrombopag + itraconazole: n=13 
 
3) Part C; Rifampin, a strong CYP3A and moderate CYP2C9 dual 
inducer 
After Cmax was reached, mean plasma concentrations of avatrombopag during 
coadministration with rifampin declined more rapidly than those of avatrombopag 
administered alone (Figure 2-3).  Coadministration of rifampin resulted in no apparent 
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difference in Cmax or tmax but did lead to an approximately 0.5-fold decrease in AUC and 
a 0.5-fold shortening of t½ (20.3 h for avatrombopag alone vs. 9.77 h for 
avatrombopag+rifampin) were observed (Table 2-3). 
The platelet count on coadministration with rifampin returned to baseline level by 
approximately Day 14, i.e. 7 days after administration of avatrombopag with rifampin, 
while the platelet count on administration avatrombopag alone returned to baseline by 
27 days after administration of avatrombopag.  Further to this faster return to baseline 
platelet levels on coadministration with rifampin, there was approximately a 5-fold 
reduction in AUEC(0-28d) with coadministration of avatrombopag and rifampin compared 
to that of avatrombopag alone.  However, the mean difference in Emax for 
avatrombopag alone and coadministration with rifampin was not statistically significant 
(Table 2-4). 
 
Figure 2-3 Mean (+ SD) plasma concentration–time profiles of avatrombopag 
following administration of avatrombopag alone and concomitantly with rifampin. 
avatrombopag alone: n=16, avatrombopag + rifampin: n=14 
 
Discussion 
The study used fluconazole, a dual moderate inhibitor of CYP2C9 and CYP3A; 
itraconazole, a strong CYP3A only inhibitor; and rifampin, a dual inducer having strong 
inducing potency of CYP3A and moderate potency of CYP2C9.  In vitro data using 
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recombinant CYP enzyme indicated that CYP2C9 and CYP3A contributed equally to 
the metabolism of avatrombopag; no other major enzymes were identified.  The 
evaluations of the interaction with the three different interacting drugs in this study were 
expected not only to provide insights into the relative role of either CYP2C9 or CYP3A 
in metabolic clearance of avatrombopag, but also to be helpful in providing dosing 
recommendations on concomitant use of such interacting drugs with avatrombopag. 
The study designs proposed for each of these interactions were standard procedures 
intended to maximize the extent of inhibition/induction of the interacting drugs under 
steady-state dosing conditions24-26 and assessing those effects on a single dose profile of 
avatrombopag. 
 
Results demonstrated a significant increase in systemic exposure to avatrombopag 
(AUC: 2.16-fold) when coadministered with a dual inhibitor of CYP2C9 and CYP3A, 
fluconazole; a smaller effect (1.17-fold) was observed on Cmax.  Among PD parameters 
such as Emax and AUEC(0-28d), for clinical practice, physicians refer to the maximum 
increase in platelet count; thus, Emax is the determining factor for making decisions on 
whether the patients require platelet transfusion27-29.  However, AUEC(0-28d) is also 
useful when considering clinical relevance.  For example, a greater than 20×109/L 
increase in Emax caused by fluconazole coadministration might become a trigger of the 
event of portal vein thrombosis and thrombophlebitis septic.  Thus, the finding that 
AUEC(0-28d) was significantly increased by fluconazole co-administration is clinically 
important.  Accordingly, dose adjustment of avatrombopag might be needed when 
coadministered with dual inhibitors of CYP3A and CY2C9.   
 
In contrast, a strong CYP3A inhibitor, itraconazole, had milder effects on the 
avatrombopag PK and PD than those of fluconazole.  Even though inhibition by 
itraconazole is known to be a less potent CYP inhibitor compared to ketoconazole21, the 
PBPK simulation results predicted that ketoconazole would also have a milder effect on 
the avatrombopag than those of fluconazole.  As itraconazole is known to have no 
impact on CYP2C9 activity19,20, the substantial impact of fluconazole suggests that 
CYP2C9 may play a more dominant role in metabolic clearance of avatrombopag than 
CYP3A.   
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Coadministration with a dual inducer of CYP2C9 and CYP3A, rifampin, demonstrated 
an approximately 0.5-fold decrease in AUC without any effect on Cmax.  
Avatrombopag t½ was shortened by approximately 10 h when coadministered with 
rifampin.  Taken together with drug interactions seen with inhibitors, the results of 
coadministration with rifampin is likely to be driven primarily by CYP2C9 induction.  
Regarding the impact of coadministration of rifampin on the platelet count profile, there 
was an approximate 5-fold reduction in AUEC(0-28d) without any impact on Emax.  Even 
though Emax is more relevant in influencing the decisions on need of platelet 
transfusions for a patient requiring a surgical procedure, a 5-fold reduction in 
AUEC(0-28d) has significant clinical impact. 
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Chapter 3  Population PK/PD analyses of Avatrombopag in 
Patients with Chronic Liver Disease  
 
 
Introduction 
The objectives of this analysis were to describe the PK characteristics of avatrombopag 
in healthy subjects and patients with chronic liver disease (CLD), to compare the PK in 
CLD patients to that in healthy subjects, and to identify covariates that explain 
interindividual variability (IIV) in PK.  The PK/PD relationship between 
avatrombopag plasma concentration and platelet count and examined covariates that 
might affect the PK/PD relationship in CLD patients with thrombocytopenia were 
assessed. 
 
Method 
For the population PK analysis, data from 787 healthy subjects and patients with CLD 
and thrombocytopenia were pooled from 10 phase 1 studies, 2 phase 2 studies, and 2 
phase 3 studies in Table 3-1.  The PK/PD analysis data set for platelet count consisted 
of pooled data from 396 patients with CLD from 2 phase 2 and 2 phase 3 studies.  All 
protocols were approved by the local IRB for each of the study sites, and all subjects 
provided signed consent.  All studies were conducted in accordance with the principles 
of the Declaration of Helsinki and Good Clinical Practice guidelines. 
The PK and PK/PD models were developed using nonlinear mixed-effects modeling 
software (NONMEM) version 7.3 interfaced with PDx-Pop version 5.2 (ICON 
Development Solutions, Ellicott City, Maryland). 
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Table 3-1  Description of Studies included in Population PK and PK/PD 
Study description Subjects (M/F)a Design Samples
b Dose/ Formulation/ Food condition 
Single dose escalation HV (27/15) DB 18/0 1-100 mg, SUS, fasting 
Multiple dose escalation HV (13/6) DB 32/0 3-20 mg QD, SUS, fasting 
Relative BA, SUS-1G HV (15/2) OL, XO 51/0 10 mg, SUS-1G fasting and fed 
TQTS HV (15/31) DB, XO 12/0 100 mg, 1G, fastingc 
Relative BA, 1G-2G HV (13/3) OL, XO 39/0 40 mg, 1G-2G, fasting and fedc 
Single, and multiple dose escalation in 
Japanese, Chinese and White  HV (29/12) DB, XO 64/0 10-80 mg, 10 mg QD, 2G,fasting 
Relative BA, two-Lots, intra-subject 
variability HV (35/7) OL, XO 60/0 40 mg, 2G, fasting 
Effect of food, high-fat  HV (71/13) OL 30/0 40 mg, 2G, fasting and fed 
Effect of food, low-fat HV (17/19) OL 48/0 40 mg, 2G, fasting and fed 
Single dose escalation in Japanese and White HV (24/24) OL 70/0 20-60 mg, 2G, fasting and fed 
Phase 2, dose-finding study  PTS (62/31) DB, PG 6/11 100 mg L+ 20-80 mg, 80 mg L + 10-20 mg, 1Gc-2G, fasting 
Phase 2, dose-finding study in Japanese PTS (19/9) DB, PG 3/6 20-60 mg QD, 2G, fed 
Phase 3 pivotal study PTS (100/47) DB, PG 3/6 40, 60 mg QD, 2G, fed 
Phase 3 pivotal study PTS (83/45) DB, PG 3/6 40, 60 mg QD, 2G, fed 
BA, bioavailability; HV, healthy volunteer; Form, formulation; MD, multiple dose; OL, open-label; PG, parallel group; PTS, 
patients with thrombocytopenia with liver disease prior to elective procedure; QD, once daily; SUS, suspension; SD, single dose; 
TQTS, through QT study; XO, cross-over; 1G, 1st generation tablet; 2G, 2nd generation tablet. 
a. number of subjects to be included in the analysis; b. median number of PK/ PD samples per subject used in analyses; c. Lot 
56789-101 of 1G. 
 
PK Model for Avatrombopag 
The pooled PK data set included 15515 avatrombopag plasma concentrations from a 
total of 787 subjects, of which 1414 plasma concentrations were from 396 patients with 
CLD.  A summary of the demographics and covariates included in the population PK 
analysis is presented in Table 3-2.   
 
Table 3-2  Characteristics for Population Pharmacokinetic Dataset (N=787) 
Continuous characteristic Median (range) Discrete characteristics Frequency 
Age (y) 47 (18–86) Subjects (healthy/patients) 391/396 
Body weight (kg) 75 (39-175) Sex (male/female) 524/263 
ALP (U/L) 81 (19-1589) Race (Caucasian/Black/Asian/ Other) 522/59/179/27 
AST (U/L) 29 (9-377) Formulation (suspension/1Gb/2G)c 77/130/612 
ALT (U/L) 25 (6-304) Food condition (fasted/fed/unknown) 273/421/93 
CRCL (mL/min) 115 (26-509) Concomitant proton pomp inhibitor (Yes/No) 173/614 
Bilirubin (mg/dL) 16 (3-176) Concomitant H2-blocker (Yes/No) 18/769 
Albumin (g/dL) 42 (18-53) Concomitant CYP3A inhibitor (Yes/No) 12/775 
INR 1.1 (0.9-3.4) Concomitant Antacids (Yes/No) 10/777 
eGFR (mL/min)a 96 (30-208) Concomitant P-gp inhibitors (Yes/No) 25/762 
  Child Turcotte Pugh (5-6/7-9/10-15/healthy/Missing) 212/151/31/391/2 
  MELD score (≤9/>9/healthy/Missing) 126/269/391/1 
  Etiology of chronic liver disease (viral hepatitis/ 
Non-alcoholic steatohepatitis/ Alcoholic /Other) 242/45/49/60 
a: Upper limit was capped at 150 mL/min when tested as a covariate; b: Of 130, 113 is 1G Tablet of Lot 56789-101; c: a total 
number of subjects; ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; CRCL, creatinine 
clearance; eGFR, estimated glomerular filtration rate; MELD score, Model for end stage liver disease; P-gp, P-glycoprotein. 
 
A total of 3 formulations were developed during the course of the clinical development: 
a suspension formulation for initial phase 1 studies, a designated first-generation (1G) 
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tablet formulation for subsequent phase 1 and phase 2 studies, and a final 
to-be-marketed second-generation (2G) tablet formulation for phase 1 multiple clinical 
pharmacology/biopharmaceutical studies, phase 2 studies, and phase 3 studies.  One 
lot of the 1G tablet formulation (Lot 56789-101) was found to have manufacturing 
issues related to powder flow and content uniformity with reduced bioavailability 
relative to other 1G and 2G lots; therefore, this lot was distinguished for modeling 
purposes.  Of 15515 avatrombopag plasma concentrations, 1461 from suspension 
formulation, 1491 from 1G tablet (including 987 samples associated with Lot 
56789-101), and 12563 from 2G tablets were available for population PK analysis.  
None of the subjects in the PK data set received concomitant CYP3A4 inducers or 
CYP2C9 inducers or inhibitors.  Based on a graphic analysis of avatrombopag 
concentration-time profiles, the process of model building initiated with fitting a 
1-compartment model to the data and proceeding to more suitable effects added or 
deleted one at a time.  One-compartment models with either first-order absorption 
(absorption rate constant [Ka]) or simultaneous zero (duration of absorption [D1]) and 
first-order absorption with lag time and first-order elimination from the central 
compartment were tested with the first-order conditional estimation with interaction.  
Relative bioavailability (F1) to the suspension for 1G tablet (Lot 56789-101) and other 
1G and 2G tablets were tested.  Based on model development both Ka and F1 for the 
other 1G tablet was similar to that for the 2G tablet, and hence common Ka and F1 
parameters were used for other 1G and 2G tablets in all subsequent analyses.  The 
effect of food on Ka, D1, and F1, and the effect of formulation on Ka and D1 were 
tested.  Residual error was best described by a combined additive and proportional 
error for time after dose ≤4 hours and another for time after dose >4 hours.  The IIV 
was estimated for all parameters except for lag time using an exponential error structure, 
which assumed log-normal distribution for PK parameters.  Interoccasion variability 
(IOV) on F1 parameters was also assessed. 
Model development was initially attempted using pooled full profile data from all 
studies; however the model was unstable and did not converge successfully despite a 
very large drop in the objective function when modeling IOV on F1 for the 1G and 2G 
tablets.  Therefore, a PK base model was developed based on phase 1 study data only, 
followed by PK base model development for all data where population parameter 
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estimates for Ka, D1, F1, and IOV on F1, but not their IIV, obtained from PK base 
model development based on phase 1 were fixed.  The residual variability was 
assessed by proportional and combined additive/proportional error structures, with all 
permutations of IIV and residual variability error structures tested systematically.  The 
following criteria were considered to assess the model selection: (1) a P value of .01 for 
1 additional parameter; (2) the successful convergence of the minimization procedure; 
(3) at least 3 significant digits; (4) termination of covariance step without any error 
message; and (5) relative standard errors of the estimates >50%.  In addition, 
goodness-of-fit plots of the population and individual predicted concentration vs 
observed concentrations, plots of conditioned weighted residuals vs population 
predictions, and conditioned weighted residuals vs time were used to assess the PK 
model.  The final population PK model for avatrombopag was validated using the 
visual predictive check30 and bootstrap resampling technique31.  Bootstrap estimates 
were used to compute CIs for all model parameters, including those for the covariate 
estimates.  Two hundred bootstrap replicates of the actual data set were performed. 
 
PK/PD Model for Platelet Count 
The pooled population PK/PD data set included 1877 platelet count-time data from 394 
patients with CLD.  A summary of the demographics and covariates included in the 
PK/PD analysis is presented in Table 3-3.   
 
Table 3-3  Characteristics for Pharmacokinetic/Pharmacodynamic Analysis 
(N=394) 
Continuous characteristic Median (range) Discrete characteristics Frequency 
Age (y) 58 (19–86) Subjects (healthy/patients) 0/394 
Body weight (kg) 79 (39-175) Sex (male/female) 264/130 
Albumin (g/dL) 34 (18-49) Race (Caucasian/Black/East Asiana/Asian/ Other) 239/15/107/16/17 
Baseline platelet count 
(109/L) 
39 (10-107) Baseline platelet count (< 30/≥30 to <40/40≤) 
(109/L) 69/148/177 
Baseline TPO (U/L) 100 (31-895) Hepatocellular carcinoma (Yes/No) 86/308 
  Splenomegaly (Yes/No) 190/204 
  Presence of anti-platelet therapy (Yes/No) 2/392 
  Concomitant steroid therapy (Yes/No) 13/381 
  Child Turcotte Pugh (5-6/7-9/10-15) 212/151/31 
  MELD score (≤9/>9/Missing) 126/267/1 
  Etiology of chronic liver disease (viral hepatitis/ 
Non-alcoholic steatohepatitis/ Alcohoric /Other) 241/44/49/60 
a: Japanese, Chinese and Koreans; MELD score, Model for end stage liver disease; TPO, thrombopoietin. 
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A 6-compartment PK/PD life-span model with a linear relationship for drug effect, with 
2 PK compartments (absorption and disposition) and 4 PD compartments, was applied 
to platelet count data, as depicted in Figure 3-1.  Individual post hoc estimates from the 
final PK model were used as the PK exposure input for the PK/PD model, and the 
PK/PD model was constructed using the first-order conditional estimation with 
interaction method.  In the PK/PD model, there was 1 precursor production 
compartment (BM1), 2 transit/maturation compartments (BM2 and BM3), and 1 platelet 
(blood) compartment (platelet) with a linear drug effect on platelet production (slope).  
The linear effect of avatrombopag on platelet count stimulation was as follows: 
Stimulation = 1 + Slope × Plasma concentration 
 
where stimulation defines the relationship between avatrombopag concentration and 
megakaryocyte production.  The residual variability was assessed by proportional, 
additive, and combined error structures.  The model was parameterized for observed 
baseline platelet count, slope for drug effect, first-order maturation rate of platelet 
precursors (Kout), and zero-order production rate of platelet precursors (Kin) with 
exponential IIV estimated for all parameters.  The criteria for assessing the model 
selection were the same as for PK model development.  Goodness-of-fit plots of the 
population and individual predicted platelet count vs observed platelet count, plots of 
weighted residuals vs population predicted platelet count, and weighted residuals vs 
time were used to assess the PK/PD model.  The final PK/PD model for avatrombopag 
was validated using the visual predictive check and bootstrap resampling technique.  
Bootstrap estimates were used to compute CIs for all model parameters, including those 
for the covariate estimates.  One hundred bootstrap replicates of the actual data set 
were performed. 
 
Covariate Model Development 
The association between subject covariates and PK or PK/PD parameters were 
performed in a stepwise fashion.  Individual Bayes post hoc PK or PK/PD parameter 
estimates generated from the basic model as well as their difference from the 
corresponding population value were plotted vs the covariates to identify potential 
relationships.  Eta shrinkage was calculated and reported for IIV parameter estimates.  
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Parameters with >30% of shrinkage were excluded from the covariate analysis.  The 
associations between PK or PK/PD and covariates were evaluated by a univariate 
addition and ranked in descending order according to the change in objective function 
value.  Variables were then tested by stepwise addition to the model.  Covariates were 
included in the model at a significance level of 1%.  When no further significant 
covariates could be included at the 1% significance level, multivariate and backward 
deletion were carried out at the 0.1% significance level, where the relative influence of 
each covariate on the model was reevaluated by deleting it from the full model on an 
individual basis.  Continuous covariates were centered at the median of the observed 
values, and categorical covariates were tested and incorporated in the model as index 
variables. 
 
Results 
1) PK Model 
The PK of avatrombopag in healthy subjects and patients with CLD was best described 
by a 1-compartment model with simultaneous first- and zero-order absorption, with lag 
time, and elimination parameterized for apparent clearance (CL/F), apparent central 
volume (V/F), Ka with an effect of tablet formulation, D1, lag time, and bioavailability 
for the 1G (excluding lot no. 56789-101) and 2G tablets, and bioavailability for the 1G 
lot no. 56789-101 relative to the suspension formulation with IIV estimated for CL/F, 
V/F, Ka, D1, and both F1 parameters.  In addition, IOV was included for F1 for the 1G 
and 2G tablets.  The population PK parameter estimates and bootstrapped 95% 
confidence interval for the final PK model of avatrombopag are presented in Table 3-4.  
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Table 3-4  Population PK Model Parameters for Avatrombopag 
Parameter Estimate (95% CI) %RSE (b) 
Shrinkage 
(%) 
Bootstrap 
Median (95% CI) 
CL/F (L/h) 6.89 (6.64 – 7.14) 1.89 29.6 6.86 (6.52 – 7.21) 
V/F = θV/F ∙ (θv_pop)pop ∙ (WT/75.3)θWT 
V/F  (L) 180 (173 – 187) 2.08 39.2 179 (170 – 189) 
  Effect of CLD subjects on V/F (Ratio) 1.65 (1.52 – 1.78) 4.13 – 1.66 (1.53 – 1.81) 
  Effect of body weight on V/F (Power function) 0.371 (0.226 – 0.516) 19.9 – 0.363 (0.175 – 0.543) 
First-order absorption rate constant for suspension - 
Ka (1/h) 5.50 Fixed – 23.5 – 
  Effect of 1G & 2G tablets on Ka 0.258 Fixed – – – 
Zero-order absorption duration - D1 (h) 4.08 Fixed – 50.3 – 
Lag time in absorption (h) 0.389 Fixed – 100 – 
F1 – Bioavailability for 1G and 2G tablet relative to 
suspension 0.745 Fixed – 41.6 – 
F1 - Bioavailability for 1G tablet (Lot No. 
56789-101) relative to suspension 0.213 Fixed – 64.1 – 
     
Inter-subject variability in CL/F (%CV) a 28.8 9.19 – 28.5 (22.6 – 34.8) 
Inter-subject variability in V/F (%CV) a 25.0 11.0 – 24.6 (19.0 – 30.6) 
Inter-subject variability in Ka (%CV) a 137.0 7.22 – 141 (113 – 175) 
Inter-subject variability in D1 (%CV) a 21.7 13.1 – 22.1 (16.4 – 29.3) 
Inter-subject variability in F1 for 1G and 2G tablet 
(%CV) a 35.9 13.2 – 36.1 (29.6 – 40.5) 
Inter-subject variability in F1 for 1G (Lot No. 
56789-101c) (%CV) a 67.7 16.8 – 67.8 (55.4 – 78.9) 
Inter-occasion variability for F1 for 1G and 2G 
tablet (%CV) a 41.1 – – – 
Proportional residual variability in avatrombopag 
concentrations  (%CV) a 16.9 0.380 – 17.1 (15.5 – 18.7) 
Additive residual variability in avatrombopag 
concentrations  (SD in ng/mL) 0.395 7.18 – 0.378 (0.228 – 0.504) 
Proportional residual variability in avatrombopag 
concentrations  for TAD ≤ 4 h (%CV) a  56.3 1.73 – 56.4 (52.3 – 60.1) 
Additive residual variability in avatrombopag 
concentrations  for TAD ≤ 4 h (SD in ng/mL) 0.338 8.77 – 0.371 (0.0032 – 0.712) 
ALB, albumin; AST, aspartate aminotransferase; CI, confidence interval; CLD, etiology of chronic liver disease; CL/F, apparent 
clearance; CV, coefficient of variation; D1, duration for zero-order absorption; F1, relative bioavailability; Ka, absorption rate 
constant; %CV, percent coefficient of variation; %RSE, percent relative standard error; POP, population (healthy subjects vs 
patients); SD, standard deviation; TAD, time after dose; V/F, apparent central volume, WT, body weight. 
a: %CV for both inter-subject and proportional residual variability is an approximation taken as the square root of the variance × 
100. The approximation is due to the expansion of the exponential function only to first-order. b: %RSE was calculated as the S.E. 
divided by the parameter estimate × 100. c: One lot of the 1G tablet formulation (Lot 56789-101) was found to have manufacturing 
issues related to powder flow and content uniformity with reduced bioavailability relative to other 1G and 2G lots; therefore, this lot 
was distinguished for modeling purposes. 
 
The population mean value for avatrombopag CL/F was estimated to be 6.89 L/h 
(percent coefficient of variation, 28.8%).  Avatrombopag CL/F was similar between 
healthy subjects and patients with CLD.  Avatrombopag V/F was observed to increase 
with increasing body weight (power = 0.371) and was 65% higher in patients compared 
to healthy subjects.  The bioavailability of 1G and 2G tablet was 74.5% relative to 
suspension.  The absorption rate constant for the 1G and 2G tablets was 25.8% of that 
for the suspension. 
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2) PK/PD Model for Platelet Count 
The final PK/PD model was a 6-compartment life-span model parameterized with slope 
for linear drug effect, Kin and Kout with an effect of East Asians (Japanese, Chinese, and 
Korean), TPO levels, and albumin on drug effect parameter of slope was selected as the 
final PK/PD model for avatrombopag effect on platelet count (Figure 3-1).   
 
 
 
Figure 3-1  Illustration of compartments for the PK/PD life-span model of 
avatrombopag. 
Stimulation defined the relationship between avatrombopag concentration and megakaryocyte production, 
calculated as 1+slope×plasma concentration. The production of platelet precursors increases in 
avatrombopag plasma concentration proportional manner. BM1, one precursor production compartment; 
BM2, two-transit compartment; BM3, maturation compartment; CL/F, apparent clearance; D1, duration 
of absorption; Gut, gastrointestinal tract; Ka, absorption rate constant; Kdeg, first-order degradation rate of 
platelet count estimated as Kin/baseline platelet count; Kin, zero-order production rate of platelet 
precursors; Kout, first-order maturation rate of platelet precursors. 
 
The parameter estimates and the results of the visual predictive check for the final 
PK/PD model are presented in Table 3-5 and Figure 3-2, respectively.  Avatrombopag 
increased the rate of platelet production in a linear manner and the production rate 
increases 1.17% per 1 ng/mL increase in plasma avatrombopag concentrations.  The 
linear effect of avatrombopag concentration on platelet production (slope) was 
approximately 32% lower in East Asians than non–East Asians and decreased with TPO 
levels and albumin expressed as (TPO/100)−0.445 and (ALB/34)−0.938, respectively. 
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Table 3-5  Population PK/PD Model Parameters for Avatrombopag in Patients 
with Chronic Liver Disease  
Parameter Estimate (95% CI) %RSEc Shrinkage (%) 
Bootstrap Median 
(95% CI) 
Slope = θslope ∙ θEast AsianRACE ∙ (TPO/100)θTPO ∙ 
(ALB/34)θALB 
Slope (mL/ng) 
0.0117 (0.0110 – 0.0124) 3.01 20.5 0.0121 (0.0101 – 0.0138) 
  Effect of East Asiana on Slope  0.678 (0.554 – 0.802) 9.35 – 0.654 (0.507 – 0.797) 
  Effect of TPO on Slope  -0.445 (-0.606 – -0.284) 18.4 – -0.357 (-0.669 – -0.124) 
  Effect of ALB on Slope  -0.938 (-1.23 – -0.644) 16.0 – -0.669 (-1.91 – 0.0685) 
Kin (Gi/L/h) 1.40 (1.29 – 1.51) 4.11 50.0 1.69 (0.931 – 2.85) 
Kout (h-1) 0.0160 (0.0153 – 0.0167) 2.09 49.9 0.0158 (0.0140 – 0.0177) 
Inter-subject variability in BASE (%CV)b 15.3 6.72 – 14.7 (11.0 – 17.3) 
Inter-subject variability in SLOP (%CV)b 60.2 6.58 – 58.8 (46.3 – 73.9) 
Inter-subject variability in Kin (%CV)b 101 19.2 – 108 (2.90 – 158) 
Inter-subject variability in Kout (%CV)b 21.2 13.3 – 21.1 (7.20 – 30.5) 
Proportional residual variability in platelet 
count (%CV)b 14.0 4.28 – 13.9 (11.2 – 15.9) 
Additive residual variability in platelet count 
(*109/L) 3.38 8.95 – 3.41 (1.52 – 4.75) 
ALB, albumin; a: East Asian is included in Japanese, Chinese and Korean; b: %CV for both inter-subject/patient and proportional 
residual variability is an approximation taken as the square root of the variance x 100.  The approximation is due to the expansion 
of the exponential function only to first-order.; c: %RSE was calculated as the standard error divided by the parameter estimate x 
100. 
 
 
 
Figure 3-2  Visual predictive check of observed and model-predicted platelet 
count in patients with chronic liver disease (N = 394).  
PI, prediction interval. 
 
Discussion 
In order to characterize the PK profile of avatrombopag, pooled PK data from 14 studies 
were modeled.  The PK of avatrombopag was best described by a 1-compartment 
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model with simultaneous first- and zero-order absorption and linear elimination.  
Patients with CLD had, on average, a 65% higher avatrombopag V/F than healthy 
subjects.  V/F increased with increasing body weight; however, PK simulations 
showed no clinical relevance of this effect on exposure.  CL/F was similar between 
healthy subjects and patients, and hence exposure (AUC) of avatrombopag is 
comparable when these subjects receive the same doses.  The following intrinsic and 
extrinsic factors had no significant effect on avatrombopag PK: age, race, renal function, 
liver function, prothrombin international normalization ratio, and concomitant 
administration of proton pump inhibitors or H2 blockers.  Although coadministration 
with strong CYP3A inhibitors/inducers was shown to affect avatrombopag PK in 
previous clinical study and physiologically based PK simulations of Chapter 2, the 
effect of concomitant administration of these drugs could not be estimated in the 
population PK analysis due to the very limited number of subjects in the PK data set 
receiving concomitant CYP3A inhibitors/inducers, which is attributed to the short 
treatment duration of 5 days with avatrombopag. 
The PK/PD relationship between avatrombopag concentrations and platelet count in 
patients with CLD disease following once-daily dosing was well described by a 
6-compartment PK/PD life-span model, in which the stimulation of platelet count was 
linearly related to avatrombopag concentrations.  Due to explain the delayed PD 
response, this life-span model was superior to a model with an Emax function at the 
process of model development.  East Asian race showed a 32% lower slope than others 
in this PK/PD model.  However, the primary efficacy end points of phase 3 studies, 
that is, the proportion of subjects not requiring a platelet transfusion, demonstrated 
similarity between all patients and subgroup patients categorized by race (White, black, 
Asian, and other).  The magnitude of race effect is within the intersubject variability 
for slope (60.2%), and, hence, overall the effect of East Asians was considered minimal 
and of no clinical relevance.  An inverse relationship was identified for drug effect on 
slope with increasing albumin and TPO levels, with the power function of -0.938 
and -0.445, respectively.  However, PK/PD simulations demonstrated these effects to 
be of no clinical relevance.  Neither age, sex, Model for End-Stage Liver Disease score, 
Child-Turcotte-Pugh score, etiology of CLD, hepatocellular carcinoma, splenomegaly, 
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nor steroid coadministration had any statistically significant effect on any of the PK/PD 
parameters in patients with CLD. 
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Chapter 4  PK/PD Simulation and Optimal Dose Adjustment 
Guide 
 
 
Introduction 
In a clinical drug-drug interaction study in healthy subjects (Chapter 2), 
coadministration with CYP2C9 and CYP3A inhibitors/inducers was shown to affect 
avatrombopag PK.  Fluconazole (a dual inhibitor of CYP2C9 and CYP3A) and 
rifampin (a dual inducer of CYP2C9 and CYP3A) resulted in an approximately 2-fold 
increase and 0.5-fold decrease in avatrombopag area under the plasma drug 
concentration-time curve, respectively; no clinically important drug interactions were 
observed following coadministration with CYP3A or P-glycoprotein inhibitors. 
With the intent to further and fully assess the clinical relevance of potential drug-drug 
interactions, platelet count following avatrombopag administration with and without 
concomitant medication was simulated using the final population PK/PD model to 
explore potential dose adjustments. 
 
Method 
Deterministic simulations of platelet count were performed using the final PK/PD 
model empirical Bayes estimated parameters with intra- and intersubject variabilities 
and characteristics of patients with CLD with baseline platelet count of 20 to 
<40×109/L and 40 to <50×109/L.  Concomitant drugs used for the simulation were 
itraconazole (CYP3A inhibitor)22, verapamil (CYP3A inhibitor)32, fluconazole 
(CYP2C9 and CYP3A dual inhibitor)18, sulfaphenazole (CYP2C9 inhibitor)33, and 
rifampin (CYP3A and CYP2C9 dual inducer)34.  The apparent clearance values used in 
the simulations following coadministration of inhibitors/inducers were obtained from 
the actual clinical data in Chapter 2.  Regarding the interacting drugs which were not 
used in the clinical DDI study, the exposures were predicted using PBPK simulation and 
were used in the final population PK/PD model.  PD simulations were performed using 
the dose regimens included in phase 3 studies of avatrombopag, with and without 
concomitant medication, with dosing 60 mg for 5 days for patients with baseline platelet 
count of <40×109/L and 40 mg for 5 days for patients with baseline between 40 and 
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<50×109/L.  A comparison of the median, 10%, and 90% prediction intervals (PIs) of 
platelet count-time profiles were made to assess the impact of changes in covariates on 
platelet count. 
 
Results 
Predicted platelet count following avatrombopag administration in patients with CLD in 
the presence or absence of CYP2C9 and CYP3A inhibitors are shown in Figure 3-3 and 
Figure 3-4.  Elevations in platelet count when avatrombopag was coadministered with 
fluconazole and sulfaphenazole were predicted to be slightly higher compared to 
corresponding doses of avatrombopag administration alone.  The medians of maximal 
increase in platelet count following avatrombopag alone and concomitantly with 
fluconazole and sulfaphenazole in patients with a baseline platelet count of 20 to 
<40×109/L were 65×109/L, 96×109/L and 80×109/L, respectively.  Median of maximal 
increase in platelet count following avatrombopag alone and concomitantly with 
fluconazole and sulfaphenazole in patients with a baseline platelet count of 40 to <50×
109/L were 77×109/L, 104×109/L, and 89×109/L, respectively.  In addition to predicting 
a higher median effect on platelet count, coadministration with the above 2 inhibitors 
and itraconazole (only patients with a baseline platelet count of 40 to <50×109/L) also 
resulted in the upper limit of the 90% PI exceeding 200×109/L, the safety threshold used 
for risk of portal vein thrombosis in patients.  Simulations showed that avatrombopag 
administered for 5 days with concomitant CYP3A or CYP2C9 inhibitors (fluconazole, 
itraconazole, sulfaphenazole, or verapamil) is predicted to achieve comparable 
elevations in platelet count to those following corresponding doses of avatrombopag 
administration alone for 5 days, standard regimen, with the percentage of patients with a 
CLD exceeding 200×109/L at <10% (patients with a baseline platelet count of 40 to 
<50×109/L; <1% in avatrombopag alone vs <10%, <6%, <8%, and <3% in fluconazole, 
itraconazole, sulfaphenazole, and verapamil, respectively).  Meanwhile, elevations in 
platelet count when avatrombopag was coadministered with dual strong CYP3A4 and 
moderate CYP2C9 inducer (rifampin) at standard regimen were predicted to be lower 
compared to corresponding doses of avatrombopag administered alone.  The medians 
of maximal increase in platelet count following avatrombopag alone and concomitantly 
with rifampin in patients with a baseline platelet count of 20 to <40×109/L were 
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66×109/L and 47×109/L, respectively, and in patients with a baseline platelet count of 40 
to<50×109/L, the corresponding medians for maximal increase were 77×109/L and 
61×109/L, respectively, indicating that despite the decrease in exposure with 
concomitant rifampin, the majority of patients will achieve a target platelet count above 
50×109/L.  
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Figure 4-1  Predicted platelet count following avatrombopag administration in 
patients with chronic liver disease in the presence or absence of CYP2C9 and 
CYP3A inhibitors. 
PI, prediction interval.  
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Figure 4-2  Predicted platelet count following avatrombopag administration in 
patients with chronic liver disease in the presence or absence of CYP2C9 and 
CYP3A inducers. 
PI, prediction interval. 
 
Discussion 
Based on the population PK/PD simulations of platelet count and the percentage of 
CLD subjects predicted to exceed a platelet count of >200×109/L, the safety threshold 
used for risk of portal vein thrombosis in patients, a comparable increase in platelet 
count was achieved with and without concomitant CYP3A and CYP2C9 inhibitors for 
the same dosing regimens of 60 mg for 5 days with baseline platelet count between 20 
and <40×109/L and 40 mg for 5 days for baseline platelet count between 40 
and<50×109/L.  Simulations demonstrated that coadministration with strong CYP3A 
and moderate CYP2C9 inducers resulted in lower elevation in platelet count compared 
to corresponding doses of avatrombopag administered alone, and the median difference 
was approximately 20×109/L. However, considering the short duration (5 days) of 
avatrombopag treatment subjects with CLD are administered prior to their planned 
surgery and confirmation that target platelet elevation was achieved, this difference is 
not clinically important. 
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Overall Discussion and Conclusion 
 
Author mainly conducted clinical studies to clarify the characteristics of avatrombopag 
PK and PD; propose and develop a study design of Chapter 1 and Chapter 2; lead 
authorship of all clinical-related documents (e.g., clinical protocols, study reference 
manual, study reports, and publication); interpret the population PK/PD modeling and 
simulation of Chapter 3 and Chapter 4.  The following conclusions were obtained from 
these clinical studies: 
In Chapter 1, the PK and PD properties of single dose were characterized in healthy 
subjects.  Avatrombopag showed linear PK across a range of 20 to 60 mg dose, 
relatively slow absorption with peak exposure at 6 to 8 h postdose, and elimination with 
approximately 19 h of t½; tmax and t½ were constant and independent of dose increase.  
Considering avatrombopag characteristics such as poor aqueous solubility and the slow 
absorption, avatrombopag might be partially absorbed via the lymphatics.  Food intake 
affected reduction of inter- and intrasubject variability in PK without influencing the 
rate or extent of absorption; this finding was considered clinically important, therefore 
administration under fed condition was recommended for clinical use.  Platelet count 
increased dose-proportionally, reaching a maximum by 11 days postdose and then 
returning to baseline level by 27 days postdose.  This delayed response of platelet 
count was expected based on the mechanism of action.  The PK and PD of 
avatrombopag were similar between Japanese and White subjects. 
In vitro data indicated that avatrombopag is primarily metabolized by CYP3A and 
CYP2C9.  Physiologically based PK modelling predicted a potential for clinically 
important interactions, but left uncertainty as to whether or not clinically important 
effects were limited to strong inhibitors and/or inducers of these pathways.  Therefore, 
in Chapter 2, a 3-Part clinical drug-drug interaction study assessing three different 
interacting drugs was proposed to provide insights into the relative role of CYP2C9 and 
CYP3A in metabolic clearance of avatrombopag.  Itraconazole, a strong CYP3A 
inhibitor which does not impact CYP2C9, was found to have a milder effect on the 
avatrombopag PK than that of fluconazole, which is known to moderately inhibit both 
CYP3A and CYP2C9 activity19,20.  Hence, these results suggested that CYP2C9 may 
play a more predominant role in metabolic clearance of avatrombopag than CYP3A.  
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Taken together with drug interactions seen with inhibitors, the reduction in exposure of 
avatrombopag following codaministration with rifampin, a dual inducer of CYP2C9 and 
CYP3A, is also likely to be driven primarily by CYP2C9 induction.  Relative to the 
magnitude of these interactions on avatrombopag PK, coadministration with 
inhibitors/inducers resulted in smaller magnitude of effects on avatrombopag PD.  This 
could be attributed to the indirect effect of avatrombopag on platelet count.  To further 
examine these PK and PD relationships, a PK/PD model was planned. 
In Chapter 3, a population PK/PD model was developed to characterize the relationship 
between plasma avatrombopag concentrations and platelet count in patients with CLD 
patients.  The final population PK/PD model was well described by a 6-compartment 
life-span model, in which the stimulation of platelet count was linearly related 
avatrombopag concentrations, and was included statistically effects of body weight and 
CLD population on avatrombopag V/F, East Asian race, TPO level and albumin on the 
PK/PD slope parameter.  The magnitude of these covariates was within the intersubject 
variability for relative bioavailability (41.1%) and slope (60.2%), hence, overall the 
effects of these covariates was considered minimal and of no clinical relevance.  It also 
can be explained that the effects of these covariates is no clinically meaningful since the 
subgroup analysis of phase 3 did not show the racial differences and simulation using 
the various covariate values showed no clinical relevance on PK and platelet count. 
Although coadministration with CYP2C9 and CYP3A inhibitors/inducers was shown to 
affect avatrombopag PK in clinical drug-drug interaction study, the effect of 
concomitant administration of these drugs could not be estimated in the population PK 
analysis due to the very limited number of subjects in the PK data set receiving 
concomitant inhibitors/inducers.  Therefore，in Chapter 4, deterministic simulations of 
platelet count were performed using the final PKPD model in order to investigate 
further drug-drug interaction for guiding safe and effective dose.  A safety threshold of 
platelet count used for risk of portal vein thrombosis in patients is known as 200×109/L.  
PK/PD simulations showed comparable elevation in platelet count with and without 
concomitant CYP2C9 and CYP3A inhibitors for the dosing regimens of 40 and 60 mg 
for 5 days, with less than 10% frequency of platelet with CLD exceeding platelet count 
>200×109/L.  Meanwhile, despite the decrease in exposure (i.e., 0.5-fold decrease of 
AUC) with concomitant rifampin, the majority of patients were predicted to achieve a 
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target platelet count >50×109/L7.  Consequently, author concluded that dose 
adjustment is not necessary with concomitant use of CYP2C9 and CYP3A interacting 
drugs considering the short treatment duration (i.e., 5 days) and lack of significant 
safety concerns in CLD patients. 
This clinical pharmacology program not only clarified the characteristics of PK and PD 
but also provided critical assessments guiding the appropriate avatrombopag dosage 
regimen.  Although nonclinical (in vitro) data can identify CYP isoforms associated 
with metabolism, these data cannot clarify accurately the relative proportion of 
elimination related to each pathway.  PBPK modelling predicted a potential for 
clinically important interactions, but left uncertainty as to whether or not clinically 
important effects were limited to strong inhibitors and/or inducers of these pathways.  
Hence, author conducted the clinical drug-drug interaction study to assess the clinically 
important effects in healthy subjects.  The results from this study suggested that 
dose/duration adjustment is recommended when avatrombopag is coadministered with 
CYP2C9 and CYP3A inhibitors, and coadministration with strong inducers is not 
recommended.  However, author eventually concluded no dose adjustment of 
avatrombopag was needed with CYP2C9 and CYP3A inhibitors/inducers in patients 
based on the population PK/PD simulation.  The reason for different conclusion is that 
PD simulation was performed using platelet count of actual patients with CLD, unlike 
clinical study in healthy subjects.  Although an analysis of clinical data only from 
healthy subjects is insufficient to evaluate the safety and to optimize the dosage regimen, 
the present integrated PK and PD analyses would enable improved pharmacotherapy by 
predicting effectiveness, safety, and optimized dosage for the target patient.    
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